Baird downgrades Amgen to a 'underperform' rating

Amgen stock dips after Baird downgrades the biotechnology company to a ‘underperform’ on the firm’s soft 2020 guidance. Brian Skorney, Robert W Baird Research Analyst joins the On The Move panel to discuss why he believes Amgen isn’t going to do well in 2020.